FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Fischer Medical Ventures Ltd held its Board Meeting on May 29, 2026, approving the audited financial results for Q4 and FY ended March 31, 2026. On standalone basis, the company reported a loss of Rs. 1,050.58 lakhs for FY26 compared to a profit of Rs. 96.08 lakhs in FY25, with revenue declining to Rs. 2,088.52 lakhs from Rs. 867.67 lakhs. However, consolidated results show strong performance with revenue of Rs. 32,088.93 lakhs and profit of Rs. 3,101.94 lakhs, indicating subsidiaries are the primary profit drivers. The Board recommended a final dividend of Rs. 0.05 per equity share for FY26, subject to shareholder approval at the AGM. Statutory auditors M/s. Bilimoria Mehta & Co. issued an unmodified opinion. New internal auditors S. Ramanand Aiyer & Co. were appointed for FY 2026-27.
The significant swing to standalone loss may create short-term negative sentiment, though the strong consolidated performance and dividend recommendation provide some support. The company appears to be restructuring its subsidiary holdings, which could be positive for long-term value.